{"id":61912,"date":"2022-09-05T16:35:00","date_gmt":"2022-09-05T11:05:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=61912"},"modified":"2022-09-05T16:31:34","modified_gmt":"2022-09-05T11:01:34","slug":"brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/","title":{"rendered":"Brokerages see up to 35% upside in this stock after it demerged its pharma business"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-4080322687\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Piramal Enterprises Limited has demerged its pharma business and the stock started trading ex-pharma on August 30, 2022. The National Company Law Tribunal (NCLT) approved the demerger of Piramal Enterprises\u2019 Pharma business and the simplification of the company\u2019s corporate structure last month. Further, it will increase liquidity for shareholders.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3540392799\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>The diversified company\u2019s financial business contributes about 50% of its revenues and the demerger will help its pharma business to flourish on a standalone level.<\/p><p>Eligible shareholders will receive 4 shares of Piramal Pharma, with a face value of \u20b9 10 each for one fully paid-up equity share in Piramal Enterprises Limited (with a face value of \u20b9 2 each) held by them. These shares will get listed tentatively by October or November this year, subject to regulatory approvals.<\/p><p>The promoters of Piramal Enterprises Limited will have 44 per cent holdings in Piramal Enterprises. Global investment firm Carlyle will hold 20 per cent in Piramal Pharma. Other shareholders will hold a 56 per cent holding in Piramal Enterprises and a 45 per cent holding in Piramal Pharma. It is important to note that the company\u2019s promoters have been divesting their stake gradually. It was 46.1% as of March 2021 and 43.5% as of June 30, 2022. This is not a good sign.<\/p><div class=\"trade-content_5\" id=\"trade-640837297\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h4 class=\"wp-block-heading\"><strong>Targets<\/strong><\/h4><p>Jefferies has maintained a buy rating on the shares with a target price of \u20b9 1250 apiece. This translates to an upside of 24.14 per cent as compared to its current share price of \u20b9 1006.95. It said that a pick-up in retail disbursements, esp in housing, should lift loan growth.<\/p><p>ICICI Securities is bullish on the shares post demerger and has given a target price of \u20b9 1391 per share. This indicates an upside of 38.13% as compared to the company\u2019s current share price.<\/p><h4 class=\"wp-block-heading\"><strong>Price movement<\/strong><\/h4><p>The share price of Piramal enterprises increased from \u20b9 571 levels to \u20b9 1118 on August 30, 2022. In the past five trading sessions, it has increased by 73.82%. However, it has fallen by 10% in the last four trading sessions. The stock price has come under pressure after the demerger. Analysts say that the demerger has not excited investors.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Simran Bafna<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png\" alt=\"\" class=\"wp-image-26306\" width=\"256\" height=\"256\"\/><\/figure><\/div><p><strong>The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-2426844043\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Piramal Enterprises Limited has demerged its pharma business and the stock started trading ex-pharma on August 30, 2022. The National Company Law Tribunal (NCLT) approved the demerger of Piramal Enterprises\u2019 Pharma business and the simplification of the company\u2019s corporate structure last month. Further, it will increase liquidity for shareholders. The diversified company\u2019s financial business contributes [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":49884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[],"class_list":["post-61912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Brokerages see up to 35% upside in this stock after it demerged its pharma business - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brokerages see up to 35% upside in this stock after it demerged its pharma business\" \/>\n<meta property=\"og:description\" content=\"Piramal Enterprises Limited has demerged its pharma business and the stock started trading ex-pharma on August 30, 2022. The National Company Law Tribunal (NCLT) approved the demerger of Piramal Enterprises\u2019 Pharma business and the simplification of the company\u2019s corporate structure last month. Further, it will increase liquidity for shareholders. The diversified company\u2019s financial business contributes [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-05T11:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/\",\"url\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/\",\"name\":\"Brokerages see up to 35% upside in this stock after it demerged its pharma business - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"datePublished\":\"2022-09-05T11:05:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brokerages see up to 35% upside in this stock after it demerged its pharma business\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Brokerages see up to 35% upside in this stock after it demerged its pharma business - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/","og_locale":"en_US","og_type":"article","og_title":"Brokerages see up to 35% upside in this stock after it demerged its pharma business","og_description":"Piramal Enterprises Limited has demerged its pharma business and the stock started trading ex-pharma on August 30, 2022. The National Company Law Tribunal (NCLT) approved the demerger of Piramal Enterprises\u2019 Pharma business and the simplification of the company\u2019s corporate structure last month. Further, it will increase liquidity for shareholders. The diversified company\u2019s financial business contributes [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2022-09-05T11:05:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/","url":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/","name":"Brokerages see up to 35% upside in this stock after it demerged its pharma business - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","datePublished":"2022-09-05T11:05:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-35-upside-in-this-stock-after-it-demerged-its-pharma-business\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Brokerages see up to 35% upside in this stock after it demerged its pharma business"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/61912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=61912"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/61912\/revisions"}],"predecessor-version":[{"id":61913,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/61912\/revisions\/61913"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/49884"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=61912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=61912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=61912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}